GuidelineRheumatology (Oxford, England)2025
The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis.
Guideline in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- Clinical phenotypes of ANCA-associated vasculitis using ensemble clustering: prognostic and therapeutic insights from two Japanese cohorts.Rheumatology (Oxford, England) · 2026Article
- Accounting for Oral Corticosteroids Tapering and Reduction in Adverse Effect Burden in Health Economic Evaluations: External Assessment Group Perspective.PharmacoEconomics · 2026Article
- Epidemiology, clinical management, and outcomes in patients with eosinophilic granulomatosis with polyangiitis in England: A retrospective observational cohort study.The journal of allergy and clinical immunology. Global · 2026Article
- Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe kidney involvement.Clinical kidney journal · 2026Article
- Article
- Therapeutic plasma exchange in paediatric ANCA-associated vasculitis: a multicentre real-world experience.Rheumatology (Oxford, England) · 2026Observational
- Review
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Systemic Immunosuppression to Reduce Surgical Intervention in ANCA-Negative Subglottic Stenosis.The Laryngoscope · 2026Article
- When Fatigue Was Vasculitis: A Case of Limited PR3 ANCA-Positive Granulomatosis With Polyangiitis.Cureus · 2026Article
- Clinical and Echocardiographic Predictors of Major Adverse Cardiovascular Events in ANCA-Associated Vasculitis.Medicina (Kaunas, Lithuania) · 2026Article
- Granulomatosis With Polyangiitis: A Case of a 62-Year-Old Female Presenting With a Fever of Unknown Origin.Cureus · 2026Article
- Article
- Management Dilemma: Myeloperoxidase (MPO)-Positive Vasculitis in a Patient With Metastatic Malignant Melanoma.Cureus · 2026Article
- Low-dose rituximab for MPO-ANCA-associated hypertrophic pachymeningitis with delayed onset of renal involvement: a case report.Frontiers in medicine · 2026Article
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study.Frontiers in allergy · 2026Article
- Long-term outcomes remain unchanged despite reduced glucocorticoid exposure in ANCA-associated vasculitis: the multicentre REVEAL cohort study.Frontiers in immunology · 2026Observational
- Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists.Rheumatology advances in practice · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
32 authors.
Funding
Abstract
ANCA-associated vasculitis (AAV) is comprised of three specific conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Since the publication of the last British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guideline for the management of adults with AAV in 2014, a plethora of randomized controlled trials, additional research and recommendations have provided novel insights into how the management of AAV can be optimized, thus improving patient quality of life. The BSR AAV Working Group (WG) reviewed published guidelines, undertook a systematic literature review and utilized expertise from specialist vasculitis centres across the UK and patient representatives to formulate a list of 26 recommendations with corresponding strength of agreement (SOA) scores. Recommendations were updated from the published 2014 BSR and BHPR guideline. The 26 recommendations encompassed five key domains: 1. Treatment for GPA and MPA; 2. Management of subglottic stenosis and ear, nose and throat (ENT) manifestations of AAV; 3. Management and treatment for EGPA; 4. Service specifications; 5. Patient education and support. These recommendations provide an update on care delivery of AAV based on current evidence and specialist opinion. In addition, we have provided research and audit recommendations to support equitable access to care and improve health outcomes. The lay summary that accompanies this abstract can be found in Supplementary Data S1, available at Rheumatology online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.